第60回日本小児血液・がん学会学術集会

Session information

Print

一般口演

第60回 日本小児血液・がん学会学術集会 » 一般口演

[_OS8] 一般口演8
骨髄増殖性疾患/MDS/JMML

Oral Session 8　Myeloproliferative disorder/MDS/JMML

Wed. Nov 14, 2018 11:10 AM - 11:50 AM 第5会場 (みやこめっせ B1F 特別展示場B)

座長:渡邊 健一郎（静岡県立こども病院血液腫瘍科）, 長谷川 大輔（聖路加国際病院小児科）

[OS8-1-1] 小児慢性期慢性骨髄性白血病（CML）に対する多施設共同観察研究CML-08：平成30年度予備解析
A multicenter, prospective study for pediatric CML in CP (JPLSG CML-08): Preliminary analysis 2018

Hiroyuki Shimada1,2, Hidemitsu Kurosawa2, Akihiro Watanabe2, Masaki Ito2, Chikako Tono2, Haruko Shima2, Yuki Yuza2, Hideki Muramatsu2, Noriko Hotta2, Masahiko Okada2, Akihiko Tanizawa2 (1.Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan, 2.The CML Committee, Japan Children’s Cancer Group, Nagoya, Japan)

[OS8-1-2] 小児慢性骨髄性白血病（CML）に対する他施設共同観察研究CML-08：平成30年度急性有害事象に関する報告
A 2018 multicenter, prospective observational study for pediatric CML in CP (JPLSG CML-08): a preliminary analysis of adverse events

Yuki Yuza1, Hiroyuki Shimada2, Hidemitsu Kurosawa2, Akihiro Watanabe2, Masaki Ito2, Chikako Tono2, Haruko Shima2, Kazuko Hamamoto2, Hideki Muramatsu2, Noriko Hotta2, Masahiko Okada2, Akihiko Tanizawa2 (1.CML Committee, Japan Children’s Cancer Group, Nagoya & Department of Hematology/Oncology, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan, 2.CML Committee, Japan Children’s Cancer Group, Nagoya, Japan)

[OS8-1-3] 小児骨髄異形成症候群に対する臍帯血移植の成績
Outcomes after cord blood transplantation for pediatric myelodysplastic syndromes in Japan

Nao Yoshida1, Kenichiro Watanabe2, Asahito Hama1, Shohei Yamamoto3, Maiko Noguchi4, Yoji Sasahara5, Hirotoshi Sakaguchi1, Yoshiko Hashii6, Atsushi Sato7, Yoshiko Atsuta8, Daiichiro Hasegawa9 (1.Department of Pediatric Hematology and Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 2.Department of Hematology and Oncology, Shizuoka Children’s Hospital, Shizuoka, Japan, 3.Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan, 4.Department of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan, 5.Department of Pediatrics, Tohoku University Hospital, Sendai, Japan, 6.Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan, 7.Department of Hematology and Oncology, Miyagi Children’s Hospital, Sendai, Japan, 8.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan, 9.Department of Hematology and Oncology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan)

[OS8-1-4] JMML症例のアザシチジン使用実態に関する後方視的研究
A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia: A report from the JCCG JMML committee

Yuko Honda1, Yuka Nanjo2, Shinsuke Hirabayashi3, Toru Meguro4, Nao Yoshida5, Hideki Muramatsu6, Harumi Kakuda7, Shuichi Ozono8, Hiroshi Moritake9, Masahiro Yasui10, Hideki Sano11, Atsushi Manabe3, Kazuo Sakashita12 (1.Department of Pediatrics, University of Occupational and Environmental Health, Japan, 2.Department of Hematology and Oncology, Miyagi Children’s Hospital, Miyagi, Japan, 3.Department of Pediatrics, St Luke’s International Hospital, Tokyo, Japan, 4.Yamagata University Faculty of Medicine, Department of Pediatrics, Yamagata, Japan, 5.Department of Pediatric Hematology and Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 6.Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan, 7.Department of Hematology and Oncology, Chiba Children’s Hospital, Chiba, Japan, 8.Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan, 9.Division of Pediatrics Faculty of Medicine, University of Miyazaki, Miyazaki, Japan, 10.Department of Hematology and Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan, 11.Fukushima Medical University Hospital, Department of Pediatric Oncology, Fukushima, Japan, 12.Nagano Children’s Hospital, Department of Hematology and Oncology, Nagano, Japan)